1. Outcomes for patients with extraprostatic prostate cancer treated with
trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Carpenter TJ, Forsythe
K, Kao J, Stone NN, Stock RG.Brachytherapy.
2010 Nov 22. [Epub ahead of print]PMID: 21106445 [PubMed - as supplied by publisher] Related citations
2. Counterpoint: there is a dose-response relationship in the low-dose rate
brachytherapy management of prostate cancer. Stock RG.Brachytherapy. 2010 Oct-Dec;9(4): 293-6;
discussion 299. Epub 2010 Sep 15. No abstract available. PMID: 20833593 [PubMed - in process]
Related citations
3. Association between number of cell phone contracts and brain tumor incidence
in nineteen U.S. States. Lehrer S, Green S, Stock
RG.J Neurooncol. 2010
Jun 30. [Epub ahead of print] PMID: 20589524 [PubMed - as supplied by publisher] Related citations
4. Current topics in the treatment of prostate cancer with low-dose-rate brachytherapy. Stock RG, Stone NN.Urol Clin North Am. 2010 Feb;37(1):83-96,
Table of Contents. Review.PMID: 20152522 [PubMed - indexed for MEDLINE] Related citations
5. Long-term outcome and toxicity of salvage brachytherapy for local failure
after initial radiotherapy for prostate cancer. Burri RJ, Stone NN,
Unger P, Stock RG.Int
J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1338-44.PMID: 20138442 [PubMed - indexed for
MEDLINE] Related citations
6. Young men have equivalent biochemical outcomes compared with older men
after treatment with brachytherapy for prostate cancer. Burri RJ, Ho AY, Forsythe
K, Cesaretti JA, Stone NN, Stock RG.Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1315-21. Epub 2010 Jan 13.PMID:
20044216 [PubMed - indexed for MEDLINE] Related citations
7. Does neoadjuvant hormonal therapy improve urinary function when given to
men with large prostates undergoing prostate brachytherapy? Stone NN, Marshall DT,
Stone JJ, Cesaretti JA, Stock RG.J
Urol. 2010 Feb;183(2):634-9. Epub 2009 Dec 16.PMID: 20018308 [PubMed - indexed for MEDLINE]
Related citations
8. Impact of hormonal therapy on intermediate risk prostate cancer treated
with combination brachytherapy and external beam irradiation. Stock RG, Yalamanchi
S, Hall SJ, Stone NN.J
Urol. 2010 Feb;183(2):546-50. Epub 2009 Dec 14. Erratum in: J Urol. 2010 Apr;183(4):1650. Yamalachi, Swati [corrected to Yalamanchi,
Swati]. PMID: 20006854 [PubMed - indexed for MEDLINE] Related citations
9. Do high radiation doses in locally advanced prostate cancer patients treated
with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity? Stone NN, Cesaretti
JA, Rosenstein B, Stock RG.Brachytherapy.
2010 Apr-Jun;9(2):114-8. Epub 2009 Oct 30.PMID: 19879812 [PubMed - indexed for MEDLINE
]Related citations
10. Local control following permanent prostate brachytherapy: effect of high
biologically effective dose on biopsy results and oncologic outcomes. Stone NN, Stock RG,
Cesaretti JA, Unger P.Int
J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):355-60. Epub 2009 Jul 23.PMID: 19632069 [PubMed
- indexed for MEDLINE] Related citations
11. Postoperative nomogram predicting the 9-year probability of prostate cancer
recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Potters L, Roach M 3rd,
Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW.Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1061-5. Epub
2009 Jun 18.PMID: 19540064 [PubMed - indexed for MEDLINE] Related citations
12. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed
by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Kao J, Packer S, Vu
HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA.Cancer. 2009 Aug 1;115(15):3571-80.PMID: 19536893
[PubMed - indexed for MEDLINE] Free Article Related citations
13. Outcomes for patients with high-grade prostate cancer treated with a combination
of brachytherapy, external beam radiotherapy and hormonal therapy. Stock RG, Cesaretti
JA, Hall SJ, Stone NN.BJU
Int. 2009 Dec;104(11):1631-6. Epub 2009 Jun 2.PMID: 19493260 [PubMed - indexed for MEDLINE]
Related citations
14. Radiation dose predicts for biochemical control in intermediate-risk prostate
cancer patients treated with low-dose-rate brachytherapy. Ho AY, Burri RJ, Cesaretti
JA, Stone NN, Stock RG.Int
J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. Epub 2009 Mar 14.PMID: 19289266 [PubMed
- indexed for MEDLINE] Related citations
15. Prognostic significance of 5-year PSA value for predicting prostate cancer
recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.Stock RG, Klein TJ, Cesaretti
JA, Stone NN.Int J
Radiat Oncol Biol Phys. 2009 Jul 1;74(3):753-8. Epub 2008 Dec 10.PMID: 19084351 [PubMed
- indexed for MEDLINE] Related citations
16. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized
candidate gene. Lehrer S, Montazem A,
Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R.J Oral Maxillofac Surg. 2009 Jan;67(1):159-61.PMID:
19070762 [PubMed - indexed for MEDLINE] Related citations
17. Counterpoint: High-risk prostate cancer: the case for combination brachytherapy
and external beam irradiation. Stock RG.Brachytherapy. 2008 Oct-Dec;7(4):280-2;
discussion 283. No abstract available. PMID: 18928921 [PubMed - indexed for MEDLINE] Related citations
18. There is no correlation between erectile dysfunction and dose to penile
bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy. Solan AN, Cesaretti
JA, Stone NN, Stock RG.Int
J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1468-74. Epub 2008 Oct 14.PMID: 18922652 [PubMed
- indexed for MEDLINE] Related citations
19. Effect of family history on outcomes in patients treated with definitive
brachytherapy for clinically localized prostate cancer. Peters CA, Stock RG,
Blacksburg SR, Stone NN.Int
J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):24-9. Epub 2008 Aug 7.PMID: 18692325 [PubMed
- indexed for MEDLINE] Related citations
20. Distant and local recurrence in patients with biochemical failure after
prostate brachytherapy. Stock RG, Cesaretti
JA, Unger P, Stone NN.Brachytherapy.
2008 Jul-Sep;7(3):217-22.PMID: 18635024 [PubMed - indexed for MEDLINE] Related citations
21. Multicenter analysis of effect of high biologic effective dose on biochemical
failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Stone NN, Potters L,
Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG.Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):341-6. Epub
2008 Jul 1.PMID: 18597953 [PubMed - indexed for MEDLINE] Related citations
22. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3
with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Burri RJ, Stock RG,
Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS.Radiat Res. 2008 Jul;170(1):49-59.PMID: 18582155 [PubMed - indexed for MEDLINE] Related citations
23. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the
jaws. Lehrer S, Montazem A,
Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Sep;106(3):389-91. Epub 2008
Jun 13.PMID: 18554944 [PubMed - indexed for MEDLINE] Related citations
24. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Kao J, Stone NN, Lavaf
A, Dumane V, Cesaretti JA, Stock RG.Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):96-101. Epub 2007 Nov 5.PMID:
17980505 [PubMed - indexed for MEDLINE] Related citations
25. Brachytherapy for the treatment of prostate cancer. Cesaretti JA, Stone
NN, Skouteris VM, Park JL, Stock RG.Cancer J. 2007 Sep-Oct;13(5):302-12. Review.PMID: 17921729 [PubMed - indexed
for MEDLINE] Related citations
26. TGFB1 single nucleotide polymorphisms are associated with adverse quality
of life in prostate cancer patients treated with radiotherapy. Peters CA, Stock RG,
Cesaretti JA, Atencio DP, Peters S, Burri RJ, Stone NN, Ostrer H, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):752-9. Epub 2007 Aug 8.PMID: 17689884 [PubMed - indexed for MEDLINE] Related citations
27. Customized dose prescription for permanent prostate brachytherapy: insights
from a multicenter analysis of dosimetry outcomes. Stone NN, Potters L,
Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW, Stock RG.Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1472-7. Epub 2007 Aug 6.PMID: 17689026 [PubMed - indexed for MEDLINE] Related citations
28. Effect of low dose-rate prostate brachytherapy on the sexual health of
men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up. Cesaretti JA, Kao J,
Stone NN, Stock RG.BJU
Int. 2007 Aug;100(2):362-7.PMID: 17617140 [PubMed - indexed for MEDLINE] Related citations
29. Possession of ATM sequence variants as predictor for late normal tissue
responses in breast cancer patients treated with radiotherapy. Ho AY, Fan G, Atencio
DP, Green S, Formenti SC, Haffty BG, Iyengar P, Bernstein JL, Stock RG, Cesaretti JA, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):677-84. Epub
2007 May 22.PMID: 17517479 [PubMed - indexed for MEDLINE] Related citations
30. A genetically determined dose-volume histogram predicts for rectal bleeding
among patients treated with prostate brachytherapy. Cesaretti JA, Stock
RG, Atencio DP, Peters SA, Peters CA, Burri RJ, Stone NN, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1410-6. Epub 2007 May 9.PMID: 17490827 [PubMed - indexed for MEDLINE] Related citations
31. Patterns of local failure following prostate brachytherapy. Stone NN, Stock RG,
White I, Unger P.J
Urol. 2007 May;177(5):1759-63; duscussion 1763-4.PMID: 17437808 [PubMed - indexed for
MEDLINE] Related citations
32. Long-term urinary, sexual, and rectal morbidity in patients treated with
iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Stone NN, Stock RG.Urology. 2007 Feb;69(2):338-42.PMID: 17320674 [PubMed - indexed for MEDLINE] Related citations
33. The effect of brachytherapy, external beam irradiation and hormonal therapy
on prostate volume. Stone NN, Stock RG.J Urol. 2007 Mar;177(3):925-8.PMID: 17296377 [PubMed - indexed for MEDLINE] Related citations
34. Is seminal vesicle implantation with permanent sources possible? A dose-volume
histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. Ho AY, Burri RJ, Jennings
GT, Stone NN, Cesaretti JA, Stock RG.Brachytherapy. 2007 Jan-Mar;6(1):38-43.PMID: 17284384 [PubMed - indexed
for MEDLINE] Related citations
35. Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5
and the MSEFS. Zagar TM, Stock RG,
Cesaretti JA, Stone NN.Brachytherapy.
2007 Jan-Mar;6(1):26-33.PMID: 17284382 [PubMed - indexed for MEDLINE] Related citations
36. Interstitial implant alone or in combination with external beam radiation
therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Frank SJ, Grimm PD,
Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M 3rd, Clarke DH, Stock RG, Robert Lee W, Michalski
JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC.Brachytherapy. 2007 Jan-Mar;6(1):2-8.PMID: 17284379 [PubMed - indexed for MEDLINE] Related citations
37. Urinary symptom flare after brachytherapy for prostate cancer is associated
with erectile dysfunction and more urinary symptoms before implantation. Lehrer S, Cesaretti
J, Stone NN, Stock RG.BJU
Int. 2006 Nov;98(5):979-81.PMID: 17034599 [PubMed - indexed for MEDLINE] Related citations
38. Changing the patterns of failure for high-risk prostate cancer patients
by optimizing local control. Stock RG, Ho A, Cesaretti
JA, Stone NN.Int J
Radiat Oncol Biol Phys. 2006 Oct 1;66(2):389-94.PMID: 16965991 [PubMed - indexed for MEDLINE]
Related citations
39. Low-dose rate prostate brachytherapy is well tolerated in patients with
a history of inflammatory bowel disease. Peters CA, Cesaretti
JA, Stone NN, Stock RG.Int
J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):424-9. Epub 2006 Aug 2.PMID: 16887295 [PubMed
- indexed for MEDLINE] Related citations
40. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Ho AY, Atencio DP, Peters
S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J,
Andreassen CN, Trop CS, Park J, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):646-55. PMID: 16751059
[PubMed - indexed for MEDLINE]R elated citations
41. High-dose-rate versus low-dose-rate monotherapy in the treatment of localized
prostate cancer: The case for low-dose-rate monotherapy. Stock RG.Brachytherapy. 2006 Jan-Mar;5(1):5-6; discussion
8. No abstract available. PMID: 16563989 [PubMed - indexed for MEDLINE] Related citations
42. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis
after postmastectomy radiotherapy. Andreassen CN, Overgaard
J, Alsner J, Overgaard M, Herskind C, Cesaretti JA, Atencio DP, Green S, Formenti SC, Stock RG, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2006 Mar
1;64(3):776-83. Epub 2005 Dec 9. PMID: 16338099 [PubMed - indexed for MEDLINE] Related citations
43. Disease-specific survival following the brachytherapy management of prostate
cancer. Stock RG, Cesaretti
JA, Stone NN.Int J
Radiat Oncol Biol Phys. 2006 Mar 1;64(3):810-6. Epub 2005 Nov 23. PMID: 16309852 [PubMed
- indexed for MEDLINE] Related citations
44. Biologically effective dose values for prostate brachytherapy: effects
on PSA failure and posttreatment biopsy results. Stock RG, Stone NN,
Cesaretti JA, Rosenstein BS.Int
J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33. Epub 2005 Oct 19.PMID: 16242258 [PubMed
- indexed for MEDLINE] Related citations
45. Critical organ dosimetry in permanent seed prostate brachytherapy: defining
the organs at risk. Crook JM, Potters L,
Stock RG, Zelefsky MJ.Brachytherapy.
2005;4(3):186-94.PMID: 16182218 [PubMed - indexed for MEDLINE] Related citations
46. Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate
cancer. Lehrer S, Diamond EJ,
Stone NN, Stock RG.BJU
Int. 2005 Aug;96(3):328-9.PMID: 16042724 [PubMed - indexed for MEDLINE] Related citations
47. Reduction of pulmonary migration of permanent interstitial sources in patients
undergoing prostate brachytherapy. Stone NN, Stock RG.Urology. 2005 Jul;66(1):119-23.PMID: 15992909 [PubMed - indexed for MEDLINE] Related citations
48. C-reactive protein is significantly associated with prostate-specific antigen
and metastatic disease in prostate cancer. Lehrer S, Diamond EJ,
Mamkine B, Droller MJ, Stone NN, Stock RG.BJU Int. 2005 May;95(7):961-2.PMID: 15839913 [PubMed - indexed for MEDLINE]
Related citations
49. Urinary morbidity and incontinence following transurethral resection of
the prostate after brachytherapy. Kollmeier MA, Stock
RG, Cesaretti J, Stone NN.J
Urol. 2005 Mar;173(3):808-12. Review.PMID: 15711274 [PubMed - indexed for MEDLINE] Related citations
50. Intermediate term biochemical-free progression and local control following
125iodine brachytherapy for prostate cancer. Stone NN, Stock RG,
Unger P.J Urol. 2005
Mar;173(3):803-7.PMID: 15711273 [PubMed - indexed for MEDLINE] Related citations
51. ATM sequence variants are predictive of adverse radiotherapy response among
patients treated for prostate cancer. Cesaretti JA, Stock
RG, Lehrer S, Atencio DA, Bernstein JL, Stone NN, Wallenstein S, Green S, Loeb K, Kollmeier M, Smith M, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2005 Jan
1;61(1):196-202.PMID: 15629612 [PubMed - indexed for MEDLINE] Related citations
52. Prostate cancer in a large prostate is associated with a decreased prostate
specific antigen failure rate after brachytherapy. Lehrer S, Stone NN,
Stock RG.J Urol. 2005
Jan;173(1):79-81.PMID: 15592033 [PubMed - indexed for MEDLINE]Related citations
53. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases.Lehrer S, Diamond EJ, Mamkine
B, Stone NN, Stock RG.Technol
Cancer Res Treat. 2004 Oct;3(5):411.PMID: 15453805 [PubMed - indexed for MEDLINE] Free Article Related citations
54. Does prior transurethral resection of prostate compromise brachytherapy
quality: a dosimetric analysis. Cesaretti JA, Stone
NN, Stock RG.Int J
Radiat Oncol Biol Phys. 2004 Oct 1;60(2):648-53.PMID: 15380602 [PubMed - indexed for MEDLINE]
Related citations
55. Combined modality treatment in the management of high-risk prostate cancer. Stock RG, Cahlon O,
Cesaretti JA, Kollmeier MA, Stone NN.Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1352-9.PMID: 15275720 [PubMed
- indexed for MEDLINE] Related citations
56. Prostate gland motion and deformation caused by needle placement during
brachytherapy. Stone NN, Roy J, Hong
S, Lo YC, Stock RG.Brachytherapy.
2002;1(3):154-60.PMID: 15090279 [PubMed - indexed for MEDLINE] Related citations
57. Preliminary toxicity and prostate-specific antigen response of a Phase
I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation
in the treatment of locally advanced prostate cancer. Stock RG, Stone NN.Brachytherapy. 2002;1(1):2-10. Review.PMID: 15062181 [PubMed - indexed for MEDLINE] Related citations
58. What is the optimal dose for 125I prostate implants? A dose-response analysis
of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Stock RG, Stone NN,
Dahlal M, Lo YC.Brachytherapy.
2002;1(2):83-9.PMID: 15062175 [PubMed - indexed for MEDLINE] Related citations
59. Prospective assessment of patient-reported long-term urinary morbidity
and associated quality of life changes after 125I prostate brachytherapy. Stone NN, Stock RG.Brachytherapy. 2003;2(1):32-9.PMID: 15062161 [PubMed - indexed for MEDLINE] Related citations
60. Comparison of intraoperative dosimetric implant representation with postimplant
dosimetry in patients receiving prostate brachytherapy. Stone NN, Hong S, Lo
YC, Howard V, Stock RG.Brachytherapy.
2003;2(1):17-25.PMID: 15062159 [PubMed - indexed for MEDLINE] Related citations
61. The role of hormonal therapy in prostate brachytherapy. Point. Stock RG.Brachytherapy. 2003;2(1):1-2. No abstract
available. PMID: 15062156 [PubMed - indexed for MEDLINE] Related citations
62. Influence of prostate volume on dosimetry results in real-time 125I seed
implantation. McNeely LK, Stone NN,
Presser J, Chircus JH, Stock RG.Int
J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):292-9.PMID: 14697451 [PubMed - indexed for
MEDLINE] Related citations
63. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up:
importance of patient selection and implant quality. Kollmeier MA, Stock
RG, Stone N.Int J Radiat
Oncol Biol Phys. 2003 Nov 1;57(3):645-53.PMID: 14529768 [PubMed - indexed for MEDLINE]
Related citations
64. Putative protein markers in the sera of men with prostatic neoplasms. Lehrer S, Roboz J, Ding
H, Zhao S, Diamond EJ, Holland JF, Stone NN, Droller MJ, Stock RG.BJU Int. 2003 Aug;92(3):223-5.PMID: 12887471 [PubMed
- indexed for MEDLINE] Related citations
65. Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer
patients carrying the I1307k allele of the APC (adenopolyposis coli) gene. Lehrer S, Diamond EJ,
Stone NN, Droller MJ, Stock RG, Stone M, Bajwa A, Kornreich R.Urol Oncol. 2003 Mar-Apr;21(2):101-4.PMID: 12856637
[PubMed - indexed for MEDLINE] Related citations
66. Urinary symptom flare following I-125 prostate brachytherapy. Cesaretti JA, Stone
NN, Stock RG.Int J
Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1085-92.PMID: 12829146 [PubMed - indexed for
MEDLINE] Related citations
67. Prostate-specific antigen bounce after prostate seed implantation for localized
prostate cancer: descriptions and implications. Stock RG, Stone NN,
Cesaretti JA.Int J
Radiat Oncol Biol Phys. 2003 Jun 1;56(2):448-53.PMID: 12738319 [PubMed - indexed for MEDLINE]
Related citations
68. Practical considerations in permanent brachytherapy for localized adenocarcinoma
of the prostate. Stone NN, Stock RG.Urol Clin North Am. 2003 May;30(2):351-62.PMID: 12735510 [PubMed - indexed for MEDLINE] Related citations
69. Association between serum triiodothyronine (t3) level and risk of disease
recurrence in men with localized prostate cancer. Lehrer S, Diamond EJ,
Bajwa AM, Kornreich R, Stagger S, Stone NN, Droller MJ, Stock RG.Prostate Cancer Prostatic Dis. 2001;4(4):232-234.PMID:
12497024 [PubMed - as supplied by publisher] Free Article Related citations
70. Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors
of advanced-stage prostate cancer .Lehrer S, Diamond EJ, Droller
MJ, Stone NN, Stock RG.J
Natl Cancer Inst. 2002 Dec 18;94(24):1893; author reply 1893-4. No abstract available. PMID:
12488486 [PubMed - indexed for MEDLINE] Free Article Related citations
71. Association between American Urologic Association (AUA) urinary symptom
score and disease stage in men with localized prostate cancer. Lehrer S, Stone NN,
Droller MJ, Stock RG.Urol
Oncol. 2002 Mar-Apr;7(2):73-6.PMID: 12474526 [PubMed - indexed for MEDLINE] Related citations
72. Serum triiodothyronine is increased in men with prostate cancer and benign
prostatic hyperplasia. Lehrer S, Diamond EJ,
Stone NN, Droller MJ, Stock RG.J
Urol. 2002 Dec;168(6):2431-3.PMID: 12441933 [PubMed - indexed for MEDLINE] Related citations
73. Serum insulin level, disease stage, prostate specific antigen (PSA) and
Gleason score in prostate cancer. Lehrer S, Diamond EJ,
Stagger S, Stone NN, Stock RG.Br
J Cancer. 2002 Sep 23;87(7):726-8.PMID: 12232754 [PubMed - indexed for MEDLINE] Free PMC Article Free textRelated citations
74. Permanent seed implantation for localized adenocarcinoma of the prostate. Stone NN, Stock RG.Curr Urol Rep. 2002 Jun;3(3):201-6. Review.PMID: 12084189 [PubMed - indexed for MEDLINE] Related citations
75. Importance of post-implant dosimetry in permanent prostate brachytherapy. Stock RG, Stone NN.Eur Urol. 2002 Apr;41(4):434-9. Review.PMID: 12074816 [PubMed - indexed for MEDLINE] Related citations
76. Complications following permanent prostate brachytherapy. Stone NN, Stock RG.Eur Urol. 2002 Apr;41(4):427-33. Review.PMID: 12074815 [PubMed - indexed for MEDLINE] Related citations
77. Role of hormonal therapy in the management of intermediate- to high-risk
prostate cancer treated with permanent radioactive seed implantation. Lee LN, Stock RG, Stone
NN.Int J Radiat Oncol
Biol Phys. 2002 Feb 1;52(2):444-52.PMID: 11872291 [PubMed - indexed for MEDLINE] Related citations
78. ATM mutations in female breast cancer patients predict for an increase
in radiation-induced late effects. Iannuzzi CM, Atencio
DP, Green S, Stock RG, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):606-13.PMID: 11849780 [PubMed
- indexed for MEDLINE] Related citations
79. Increased serum insulin associated with increased risk of prostate cancer
recurrence. Lehrer S, Diamond EJ,
Stagger S, Stone NN, Stock RG.Prostate.
2002 Jan 1;50(1):1-3.PMID: 11757030 [PubMed - indexed for MEDLINE] Related citations
80. Screening breast cancer patients for ATM mutations and polymorphisms by
using denaturing high-performance liquid chromatography. Atencio DP, Iannuzzi
CM, Green S, Stock RG, Bernstein JL, Rosenstein BS.Environ Mol Mutagen. 2001;38(2-3):200-8.PMID: 11746755 [PubMed
- indexed for MEDLINE] Related citations
81. Intraoperative planning and evaluation of permanent prostate brachytherapy:
report of the American Brachytherapy Society. Nag S, Ciezki JP, Cormack
R, Doggett S, DeWyngaert K, Edmundson GK, Stock RG, Stone NN, Yu Y, Zelefsky MJ; Clinical Research Committe, American Brachytherapy
Society.Int J Radiat
Oncol Biol Phys. 2001 Dec 1;51(5):1422-30.PMID: 11728703 [PubMed - indexed for MEDLINE]
Related citations
82. Defining the risk of developing grade 2 proctitis following 125I prostate
brachytherapy using a rectal dose-volume histogram analysis. Snyder KM, Stock RG,
Hong SM, Lo YC, Stone NN.Int
J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):335-41.PMID: 11380219 [PubMed - indexed for
MEDLINE] Related citations
83. Penile erectile function after permanent radioactive seed implantation
for treatment of prostate cancer. Stock RG, Kao J, Stone
NN.J Urol. 2001 Feb;165(2):436-9.PMID: 11176391 [PubMed - indexed for MEDLINE] Related citations
84. Body mass, age, and the APC I1307K allele in Ashkenazi Jewish prostate
cancer patients. Lehrer S, McCurdy LD,
Stock RG, Kornreich R, Stone NN, Eng C.Cancer Genet Cytogenet. 2000 Oct 15;122(2):131-3.PMID: 11106824 [PubMed
- indexed for MEDLINE] Related citations
85. Effects of neoadjuvant hormonal therapy on prostate biopsy results after
(125)I and (103)Pd seed implantation. Stone NN, Stock RG,
Unger P.Mol Urol. 2000
Fall;4(3):163-8;discussion 169-70.PMID: 11062370 [PubMed - indexed for MEDLINE] Related citations
86. The effect of disease and treatment-related factors on biopsy results after
prostate brachytherapy: implications for treatment optimization. Stock RG, Stone NN,
Kao J, Iannuzzi C, Unger P.Cancer.
2000 Oct 15;89(8):1829-34.PMID: 11042580 [PubMed - indexed for MEDLINE] Free Article Related citations
87. Postimplant dosimetry for (125)I prostate implants: definitions and factors
affecting outcome. Stock RG, Stone NN,
Lo YC, Malhado N, Kao J, DeWyngaert JK.Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):899-906.PMID: 11020588
[PubMed - indexed for MEDLINE] Related citations
88. Biopsy results after real-time ultrasound-guided transperineal implants
for stage T1-T2 prostate cancer. Stone NN, Stock RG,
Unger P, Kao J.J Endourol.
2000 May;14(4):375-80.PMID: 10910155 [PubMed - indexed for MEDLINE] Related citations
89. Neoadjuvant Hormonal Therapy Improves the Outcomes of Patients Undergoing
Radioactive Seed Implantation for Localized Prostate Cancer. Stone NN, Stock RG.Mol Urol. 1999;3(3):239-244.PMID: 10851329 [PubMed - as supplied by publisher] Related citations
90. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint)
scan for evaluation of patients for salvage brachytherapy. Fang DX, Stock RG, Stone
NN, Krynyckyi BR, Kim CK, Machac J.Tech Urol. 2000 Jun;6(2):146-50.PMID: 10798816 [PubMed - indexed for MEDLINE]
Related citations
91. Prior transurethral resection does not increase morbidity following real-time
ultrasound-guided prostate seed implantation. Stone NN, Ratnow ER,
Stock RG.Tech Urol.
2000 Jun;6(2):123-7.PMID: 10798813 [PubMed - indexed for MEDLINE] Related citations
92. Dynamic cystography can replace cystoscopy following prostate seed implantation. Stone NN, Stock RG.Tech Urol. 2000 Jun;6(2):112-6.PMID: 10798811 [PubMed - indexed for MEDLINE] Related citations
93. Intraoperative dosimetric representation of the real-time ultrasound-guided
prostate implant. Stock RG, Stone NN,
Lo YC.Tech Urol. 2000
Jun;6(2):95-8.PMID: 10798807 [PubMed - indexed for MEDLINE] Related citations
94. Prostate brachytherapy in patients with prostate volumes >/= 50 cm(3):
dosimetic analysis of implant quality. Stone NN, Stock RG.Int J Radiat Oncol Biol Phys. 2000 Mar
15;46(5):1199-204.PMID: 10725632 [PubMed - indexed for MEDLINE] Related citations
95. Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram
analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation. Stock RG, Lo YC, Gaildon
M, Stone NN.Int J Radiat
Oncol Biol Phys. 1999 Sep 1;45(2):385-9.PMID: 10487560 [PubMed - indexed for MEDLINE]
Related citations
96. Permanent radioactive seed implantation in the treatment of prostate cancer. Stock RG, Stone NN.Hematol Oncol Clin North Am. 1999 Jun;13(3):489-501.
Review.PMID: 10432424 [PubMed - indexed for MEDLINE] Related citations
97. Prostate brachytherapy: treatment strategies. Stone NN, Stock RG.J Urol. 1999 Aug;162(2):421-6.PMID: 10411050 [PubMed - indexed for MEDLINE] Related citations
98. Rectal cancer and inflammatory bowel disease: natural history and implications
for radiation therapy. Green S, Stock RG, Greenstein
AJ.Int J Radiat Oncol
Biol Phys. 1999 Jul 1;44(4):835-40.PMID: 10386640 [PubMed - indexed for MEDLINE] Related citations
99. PSA kinetics following I-125 radioactive seed implantation in the treatment
of T1-T2 prostate cancer. Iannuzzi CM, Stock RG,
Stone NN.Radiat Oncol
Investig. 1999;7(1):30-5.PMID: 10030621 [PubMed - indexed for MEDLINE] Related citations
100. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer. Stone NN, Stock RG.Mt Sinai J Med. 1999 Jan;66(1):26-30.PMID: 9989102 [PubMed - indexed for MEDLINE] Related citations
101. Does pelvic irradiation play a role in the management of prostate cancer? Stock RG, Ferrari AC,
Stone NN.Oncology (Williston
Park). 1998 Oct;12(10):1467-72; discussion 1472, 1475-6. Review.PMID: 9798200 [PubMed
- indexed for MEDLINE] Related citations
102. Perineural invasion and seminal vesicle involvement predict pelvic lymph
node metastasis in men with localized carcinoma of the prostate. Stone NN, Stock RG,
Parikh D, Yeghiayan P, Unger P.J
Urol. 1998 Nov;160(5):1722-6.PMID: 9783940 [PubMed - indexed for MEDLINE] Related citations
103. Identification of patients at increased risk for prolonged urinary retention
following radioactive seed implantation of the prostate. Terk MD, Stock RG, Stone
NN.J Urol. 1998 Oct;160(4):1379-82.
Review.PMID: 9751358 [PubMed - indexed for MEDLINE] Related citations
104. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of
the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Lehrer S, Fodor F, Stock
RG, Stone NN, Eng C, Song HK, McGovern M.Br J Cancer. 1998 Sep;78(6):771-3.PMID: 9743298 [PubMed - indexed for
MEDLINE] Free PMC Article Free textRelated citations
105. Acute urinary morbidity following I-125 interstitial implantation of the
prostate gland. Desai J, Stock RG, Stone
NN, Iannuzzi C, DeWyngaert JK.Radiat
Oncol Investig. 1998;6(3):135-41.PMID: 9652912 [PubMed - indexed for MEDLINE] Related citations
106. A dose-response study for I-125 prostate implants. Stock RG, Stone NN,
Tabert A, Iannuzzi C, DeWyngaert JK.Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):101-8.PMID: 9588923 [PubMed
- indexed for MEDLINE] Related citations
107. A survey of physics and dosimetry practice of permanent prostate brachytherapy
in the United States. Prete JJ, Prestidge
BR, Bice WS, Friedland JL, Stock RG, Grimm PD.Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):1001-5.PMID: 9531387 [PubMed
- indexed for MEDLINE] Related citations
108. A survey of current clinical practice of permanent prostate brachytherapy
in the United States. Prestidge BR, Prete
JJ, Buchholz TA, Friedland JL, Stock RG, Grimm PD, Bice WS.Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):461-5.PMID:
9457836 [PubMed - indexed for MEDLINE] Related citations
109. Enhanced radiosensitization with interferon-alpha-2b and cisplatin in the
treatment of locally advanced cervical carcinoma. Stock RG, Dottino P,
Jennings TS, Terk M, DeWyngaert JK, Beddoe AM, Cohen C.Gynecol Oncol. 1997 Dec;67(3):309-15.PMID: 9441780 [PubMed
- indexed for MEDLINE] Related citations
110. The effect of prognostic factors on therapeutic outcome following transperineal
prostate brachytherapy. Stock RG, Stone NN.Semin Surg Oncol. 1997 Nov-Dec;13(6):454-60.PMID: 9358593 [PubMed - indexed for MEDLINE] Related citations
111. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison
of the extended and modified techniques. Stone NN, Stock RG,
Unger P.J Urol. 1997
Nov;158(5):1891-4.PMID: 9334624 [PubMed - indexed for MEDLINE] Related citations
112. A new technique for performing Syed-Neblett template interstitial implants
for gynecologic malignancies using transrectal-ultrasound guidance. Stock RG, Chan K, Terk
M, Dewyngaert JK, Stone NN, Dottino P.Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):819-25.PMID: 9128957 [PubMed
- indexed for MEDLINE] Related citations
113. Seminal vesicle biopsy: accuracy and implications for staging of prostate
cancer. Linzer DG, Stock RG,
Stone NN, Ratnow R, Ianuzzi C, Unger P.Urology. 1996 Nov;48(5):757-61.PMID: 8911521 [PubMed - indexed for MEDLINE]
Related citations
114. Patterns of spread in node-positive cervical cancer: the relationship between
local control and distant metastases. Stock RG, Chen AS, Karasek
K.Cancer J Sci Am.
1996 Sep-Oct;2(5):256-62.PMID: 9166542 [PubMed - indexed for MEDLINE] Related citations
115. Prostate specific antigen findings and biopsy results following interactive
ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG, Stone NN,
DeWyngaert JK, Lavagnini P, Unger PD.Cancer. 1996 Jun 1;77(11):2386-92.PMID: 8635111 [PubMed - indexed for
MEDLINE] Related citations
116. Sexual potency following interactive ultrasound-guided brachytherapy for
prostate cancer. Stock RG, Stone NN,
Iannuzzi C.Int J Radiat
Oncol Biol Phys. 1996 May 1;35(2):267-72.PMID: 8635932 [PubMed - indexed for MEDLINE]
Related citations
117. CT findings after laparoscopic pelvic lymph node dissection and transperineal
radioactive seed implantation for prostatic carcinoma. Glajchen N, Shapiro
RD, Stock RG, Stone NN, Ramos R.AJR
Am J Roentgenol. 1996 May;166(5):1165-8.PMID: 8615263 [PubMed - indexed for MEDLINE] Free Article Related citations
118. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications
for patient selection in the radiotherapeutic management of prostate cancer. Stock RG, Stone NN,
Ianuzzi C, Unger P.Int
J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):815-21.PMID: 7591888 [PubMed - indexed for
MEDLINE] Related citations
119. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node
dissection in men with localized carcinoma of the prostate. Stone NN, Stock RG,
Unger P.J Urol. 1995
Oct;154(4):1392-6.PMID: 7658545 [PubMed - indexed for MEDLINE] Related citations
120. Locoregional therapies for early-stage prostate cancer. Stock RG.Oncology (Williston Park). 1995 Sep;9(9):803-11;
discussion 815-6. Review.PMID: 8562323 [PubMed - indexed for MEDLINE] Related citations
121. Brachytherapy for prostate cancer: real-time three-dimensional interactive
seed implantation. Stone NN, Stock RG.Tech Urol. 1995 Summer;1(2):72-80.PMID: 9118374 [PubMed - indexed for MEDLINE] Related citations
122. A modified technique allowing interactive ultrasound-guided three-dimensional
transperineal prostate implantation. Stock RG, Stone NN,
Wesson MF, DeWyngaert JK.Int
J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):219-25.PMID: 7721619 [PubMed - indexed for
MEDLINE] Related citations
123. Node-positive cervical cancer: impact of pelvic irradiation and patterns
of failure. Stock RG, Chen AS, Flickinger
JC, Kalnicki S, Seski J.Int
J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):31-6.PMID: 7995765 [PubMed - indexed for MEDLINE]
Related citations
124. A 30-year experience in the management of primary carcinoma of the vagina:
analysis of prognostic factors and treatment modalities. Stock RG, Chen AS, Seski
J.Gynecol Oncol. 1995
Jan;56(1):45-52.PMID: 7821847 [PubMed - indexed for MEDLINE] Related citations
125. The importance of brachytherapy technique in the management of primary
carcinoma of the vagina. Stock RG, Mychalczak
B, Armstrong JG, Curtin JP, Harrison LB.Int J Radiat Oncol Biol Phys. 1992;24(4):747-53.PMID: 1429100 [PubMed
- indexed for MEDLINE] Related citations
126. Administrative ethics and conflicts of interest. Stock RG.Healthc Manage Forum. 1988 Summer;1(2):6-10.
English, French. PMID: 10287874 [PubMed - indexed for MEDLINE] Related citations
127. Risk management committee of the board. Stock RG.Hosp Trustee. 1987 Mar-Apr;11(2):17-9.
No abstract available. PMID: 10282084 [PubMed - indexed for MEDLINE] Related citations
128. Coping with constraints: planning for the future. Part 3. Stock RG, Herbert SW.Dimens Health Serv. 1983 Nov;60(11):33-4.
No abstract available. PMID: 6360775 [PubMed - indexed for MEDLINE] Related citations
129. Coping with constraints: planning for the future. Part 3. Stock RG, Herbert SW.Hosp Trustee. 1983 Nov-Dec;7(6):16-7. No
abstract available. PMID: 10264209 [PubMed - indexed for MEDLINE] Related citations
130. Coping with constraints: a six-step plan. Stock RG, Herbert SW.Dimens Health Serv. 1983 Sep;60(9):37-8.
No abstract available. PMID: 6628866 [PubMed - indexed for MEDLINE] Related citations
131. Coping with constraints: employee relations. Part 2. Stock RG, Herbert SW.Hosp Trustee. 1983 Sep-Oct;7(5):19-20.
No abstract available. PMID: 10263143 [PubMed - indexed for MEDLINE] Related citations
132. Coping with constraints: a six-step plan. Part I. Stock RG, Herbert SW.Hosp Trustee. 1983 Jul-Aug;7(4):12-4. No
abstract available. PMID: 10299250 [PubMed - indexed for MEDLINE] Related citations
